SWK Q4 2024 Earnings Report

SWK EPS Results

• Actual EPS: $0.54
• Consensus EPS: $0.94
• Beat/Miss: Missed by -$0.40
• One Year Ago EPS: N/A

SWK Revenue Results

• Actual Revenue: $12.36 million
• Expected Revenue: $9.70 million
• Beat/Miss: Beat by +$2.66 million
• YoY Revenue Growth: N/A

SWK Announcement Details

• Quarter: Q4 2024
• Date: 3/19/2025
• Time: After Market Closes
• Conference Call Date: Thursday, March 20, 2025
• Conference Call Time: 10:00AM ET

SWK (NASDAQ:SWKH) Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.

SWK Q4 2024 Earnings Call Transcript

Key Takeaways

• SWK reported a strong Q4 with $8.2 million of finance segment net income, an 8% year-over-year increase in non-GAAP tangible finance book value per share to $21.15, deployment of $44 million into life science receivables, and repurchase of approximately 100,000 shares.
• The company closed and upsized core financings for commercial-stage life science firms, including a $30 million senior secured term loan to Triple Ring Technologies and a $15 million term loan to Impedimed, with $10.6 million advanced to four performing borrowers.
• SWK signed a transaction to sell its remaining performing royalty portfolio for $34 million and completed an ILUVIEN royalty buyout, generating $51.3 million of proceeds—approximately $1 billion above carrying value—and expects to free up an additional $4.5 million from FX hedges, boosting cash toward $70 million and enabling a likely special dividend.
• As of 12/31/2024, the go-forward portfolio comprises roughly $218 million of performing loans, $14 million of non-accruals (net after a 15% reserve), and equity in warrants, with an effective portfolio yield of 15.5%.
• The Entera CDMO division, rebranded as Mod3 Pharma, tripled Q4 revenue to $3.6 million and is on track for unsubsidized profitability by year-end 2025 in partnership with its strategic investor.

Presentation

[Operator]

Greetings. Welcome to the SWK Holdings Fourth Quarter 2024 conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference over to your host, Susan Xu, Investor Relations. You may begin.

[Susan Xu, Head of Investor Relations at SWK Holdings]

Thank you. Good morning, everyone, and thank you for joining SWK Holdings Fourth Quarter 2024 financial and corporate results call. Yesterday, SWK Holdings issued a press release detailing its financial results for the three months ended December 31, 2024. The press release can be found in the Investor Relations section of swkhold.com under News Releases. Before beginning today's call, I would like to make the following statement regarding forward-looking statements. Today, we will make certain forward-looking statements about future expectations, plans, events, and circumstances, including statements about our strategy, future operations, and our expectations regarding our capital allocation and cash resources. These statements are based on our current expectations, and you should not place undue reliance on these statements.

[Susan Xu, Head of Investor Relations at SWK Holdings]

Actual results may differ materially due to our risks and uncertainties, including those detailed in the risks and uncertainties factor section of SWK Holdings 10-K filed with the SEC and other filings we make with the SEC from time to time. SWK Holdings disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise. Joining me from SWK Holdings on today's call is Jody Staggs, President and CEO, and Adam Rice, CFO, who will provide an update on SWK's Fourth Quarter 2024 corporate and financial results. Jody, go ahead.

[Jody Staggs, President and CEO at SWK Holdings]

Thank you, Susan, and thanks to everyone for joining our Fourth Quarter conference call. We are pleased with SWK's Fourth Quarter performance, and the company enters 2025 on solid footing. Our Fourth Quarter was highlighted by solid financial performance, including $8.2 million of finance segment net income, improvement in the portfolio's credit quality, and $44 million of capital deployed into yielding finance receivables to life science companies. Our Non-GAAP tangible financing book value per share increased 8% year-over-year to $21.15, and with shares trading at a discount to book and given our excess capital, we have been active purchasers of our shares, having repurchased approximately 100,000 shares for $1.6 million since September 30, 2024.

[Jody Staggs, President and CEO at SWK Holdings]

During the fourth quarter, we closed an up to $8 million senior secured term loan to Triple Ring Technologies, upsized the loan to $30 million, and advanced a cumulative $10.6 million to four performing borrowers. In January, we closed an up to $15 million term loan with PetiMed, with $10 million advanced at close. These are all core SWK financings to commercial stage life science companies. Each is either public and has demonstrated the ability to raise capital or private with the support of a sponsor. Since we last spoke, three SWK finance receivables were repaid at premiums to the GAAP carrying value. In December, Veru made a $4.2 million payment to fully satisfy the FC2 royalty. The FC2 royalty generated a 45% IRR and a 2.7x MOIC. In December, MolecuLight made a final payment totaling $12.2 million to repay its term loan to SWK.

[Jody Staggs, President and CEO at SWK Holdings]

The MolecuLight term loan generated a 20% IRR and a 1.6 MOIC. SWK continues to hold equity in MolecuLight, which is carried at zero on our books. In March, ANI Pharma made a $17.25 million payment to exercise an option to buy out the Iluvien royalty. The Iluvien royalty generated a 20% IRR and a 1.8x MOIC. At December 31, 2024, we had $13.8 million of gross finance receivables on non-accrual. The non-accrual receivables have a 15% cease reserve. Thus, our net non-accrual totaled $11.7 million. This morning, we announced the signing of a transaction to sell our remaining performing royalty portfolio for $34 million. The deal is expected to close in approximately two weeks. In combination with the Iluvien buyout, the $51.3 million of proceeds from the two monetization transactions is approximately $1 million more than the carrying value at December 31, 2024.

[Jody Staggs, President and CEO at SWK Holdings]

Upon closing of the transaction, we also expect to close out a Japanese yen hedge, which will free up an additional $4.5 million of cash. Proforma for these changes, as well as a $3 million principal repayment from 4WEB in the first quarter of 2025, and using the December 31, 2024 balances, our go-forward gross portfolio consists of approximately $218 million of performing loans, $14 million of non-accruals, and approximately $5 million of equities and warrants. Our fourth quarter 2024 portfolio effective yield was 15.5%. The effective yield is the yield assuming all finance receivables pay as modeled. This figure is not adjusted for the post-quarter changes, but should be in the neighborhood of the go-forward portfolio yield, even considering the royalty sale. Finally, as of yesterday, our cash totaled over $30 million, and we have no borrowings under our revolver.

[Jody Staggs, President and CEO at SWK Holdings]

Assuming closing of the final royalty transaction and release of the FX hedge, our gross cash will total nearly $70 million. We anticipate the board will declare a dividend on the closing of the final royalty transaction. Turning to our Enteris CDMO division, which has been rebranded as Mod3 Pharma to signify its transformation into a pure-play CDMO business. We are pleased with Mod 3's 2024 result as segment division revenue totaled $3.6 million, tripling from $1.2 million in 2023. We expect continued growth in 2025, and the team is focused on positioning the business for unsubsidized profitability by year-end. We are in regular contact with our strategic partner and believe they are pleased with Mod 3's performance. With that, I will turn the call to our CFO, Adam Rice, to review the quarter's financial results.

[Adam Rice, CFO at SWK Holdings]

Thank you, Jody. Good morning, everyone. Yesterday, we reported earnings for the fourth quarter of 2024. We reported GAAP pre-tax net income of $8.6 million, or $0.70 per diluted share. Our reported fourth quarter 2024 net income of $5.9 million, after income tax expense of $2.7 million, included a $1.1 million increase in finance receivable segment revenue and a $1.3 million increase in pharmaceutical development segment revenue. The $1.1 million increase in year-over-year finance receivable segment revenue was primarily due to a $2.3 million increase in interest and fees earned on newly funded loans and royalties. The accelerated fees on early payoffs and the increase in finance receivable segment revenue was partially offset by $900,000 as a result of two investments entering non-accrual status this year.

[Adam Rice, CFO at SWK Holdings]

As of December 31, 2024, our GAAP book value per share was $23.45, a 5% increase compared to $22.33 as of December 31, 2023. Additionally, non-GAAP tangible finance book value per share totaled $21.15 as of December 31, 2024, an 8.3% increase compared to $19.53 as of December 31, 2023. Overall operating expenses, which include interest expense, pharmaceutical manufacturing, research and development expense, general and administrative expense, and provision for credit losses, were $6.6 million during fourth quarter 2024, compared to $6.8 million in fourth quarter 2023. Mod 3 operating expenses were $1.6 million in fourth quarter 2024, compared to $1.8 million in fourth quarter 2023. Finance receivable segment operating expenses were $5.3 million in fourth quarter 2024, compared to $5.6 million in fourth quarter 2023.

[Adam Rice, CFO at SWK Holdings]

The finance receivable operating segment expenses further breakdown for fourth quarter 2024 to general and administrative expenses of $2.1 million, provision for credit losses of $2 million, and interest expense of $1.2 million. For fourth quarter 2023, general and administrative expenses of $2.1 million, provision for credit losses of $2.4 million, and interest expense of $1.1 million. The decrease in finance receivable segment operating expenses was mainly due to a $400,000 decrease in provision for credit losses. The decrease in provision for credit losses is most notably attributed to the strategic exit of three non-accrual investments during the quarter. Turning to our share repurchase program, we bought back roughly 50,000 shares at a total cost of $800,000 during the quarter. Since quarter close, we have repurchased an additional 47,000 shares for a total cost of $800,000.

[Adam Rice, CFO at SWK Holdings]

Lastly, for financial reporting purposes, we have transitioned the Mod 3 segment to held for sale as of December 31, 2024. The transition to held for sale status was based on criteria set forth in GAAP accounting guidance and is related to the option purchase agreement entered into between Mod 3 and a strategic partner effective January 1, 2024. With that, I'll turn it back over to Jody.

[Jody Staggs, President and CEO at SWK Holdings]

Thank you, Adam. We enter 2025 with a healthy loan portfolio yielding in the mid-teens, as well as $30 million of gross cash. The sale of our remaining performing royalty portfolio and closeout of the FX hedge will add an additional $39 million of cash to our balance sheet, and we anticipate declaring a dividend on the closing of the final royalty transaction. Our Mod 3 CDMO division is self-sufficient and working with our strategic partner to address the sizable need for phase I and phase II nasal CDMO services. With that, let's open the call to questions.

[Operator]

Absolutely. At this time, we will be conducting a question-and-answer session. If you would like to ask a question, please press Star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press Star two if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the Star keys. One moment, please, while we poll for questions. Once again, please press Star one if you have a question or a comment. The first question comes from Scott Jensen, Private Investor. Please proceed.

[Scott Jensen, VP and Senior Financial Consultant at Charles Schwab]

Hi, good morning, Jody and team. Congratulations on so much progress since we last spoke. I guess I got a couple of questions for you. When you're thinking about a dividend, since it's such a large pile of cash, are you thinking about an ongoing dividend or a special dividend, returning some of that cash, that cash pile to shareholders?

[Jody Staggs, President and CEO at SWK Holdings]

Yeah, Scott, thanks. The board is still considering our options. I would anticipate initially a one-time special dividend. That does not mean that there might not be additional special dividends in the future, but at this time, I do not anticipate a recurring dividend.

[Scott Jensen, VP and Senior Financial Consultant at Charles Schwab]

Yeah, love it. That's what I would hope for as well. Second, as far as the buyback, where are you on the current buyback? Is that going to be something the board's going to consider about renewing or increasing the buyback?

[Jody Staggs, President and CEO at SWK Holdings]

Yeah. And Adam, if you have the email pulled up from Courtney, I might have you look and check how much room we have, but we do have enough room on our buyback. It's been interesting trying to navigate this with our blackout period. Once we go into the blackout period, the algorithm takes over, and we do not really have control over how many shares are repurchased. When we are not in the blackout period, we can direct it and be more aggressive or less aggressive. I would say we are still active repurchasers of our shares. We think, particularly with the news we announced today, shares are trading at a 20% discount.

[Jody Staggs, President and CEO at SWK Holdings]

That is an attractive use of capital. We will continue to do that. We should be out of the blackout period when we report First Quarter, roughly May 15th, in that ballpark. The program will expire. I think it expires roughly that date. We have not discussed it, but I think the board views the buyback as an attractive use of capital. I would expect, assuming everything else is equal, that the board would strongly consider reauthorizing the program for another year.

[Scott Jensen, VP and Senior Financial Consultant at Charles Schwab]

Excellent. Thank you. I just also want to say congratulations on all those workouts, Biolase, etc. Those were excellent and cleaning it up. I will get out of the queue and see if somebody else, but keep up the good work. Thank you again. I loved reading the progress.

[Jody Staggs, President and CEO at SWK Holdings]

Yep. Thank you. Appreciate the support.

[Operator]

If there are any remaining questions, please indicate so now by pressing Star one on your touchstone phone. Once again, please press Star one if you have a question or a comment. Okay. We have no further questions in the queue. I would like to turn the floor back to Jody for any closing remarks.

[Jody Staggs, President and CEO at SWK Holdings]

Thanks, John. Thank you for joining us today and for your continued support of SWK. We hope everyone has a great day. Thanks.

[Operator]

This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.

Participants

Executives

• Adam Rice, CFO
• Jody Staggs, President and CEO
• Susan Xu, Head of Investor Relations

Analysts

• Scott Jensen, VP and Senior Financial Consultant at Charles Schwab